Anti–CTLA-4 therapy requires an Fc domain for efficacy

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingram, Jessica R., Blomberg, Olga S., Rashidian, Mohammad, Ali, Lestat, Garforth, Scott, Fedorov, Elena, Fedorov, Alexander A., Bonanno, Jeffrey B., Le Gall, Camille, Crowley, Stephanie, Espinosa, Camilo, Biary, Tamara, Keliher, Edmund J., Weissleder, Ralph, Almo, Steven C., Dougan, Stephanie K., Ploegh, Hidde L., Dougan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2018
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899492/
https://www.ncbi.nlm.nih.gov/pubmed/29581255
http://dx.doi.org/10.1073/pnas.1801524115

Ejemplares similares

Ejemplares similares